Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response

INTRODUCTION: Bone marrow (BM) is an immunologically privileged site where activated autoantibody-producing B cells may survive for prolonged periods. We investigated the effect of rituximab (anti-CD20 mAb) in peripheral blood (PB) and BM B-cell and T-cell populations in active rheumatoid arthritis...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Nakou, Magda, Katsikas, Georgios, Sidiropoulos, Prodromos, Bertsias, George, Papadimitraki, Eva, Raptopoulou, Amalia, Koutala, Helen, Papadaki, Helen A, Kritikos, Herakles, Boumpas, Dimitrios T
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2009
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2745815/
https://ncbi.nlm.nih.gov/pubmed/19715572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar2798
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares